This PDF is the current document as it appeared on Public Inspection on 07/12/2012 at 08:45 am.
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of July 6, 2012 (77 FR 40069). The document announced FDA's intention to take enforcement action against all unapproved single-ingredient, immediate-release drug products that contain oxycodone hydrochloride for oral administration and are labeled for human use, and persons who manufacture or cause the manufacture or distribution of such products in interstate commerce. The document was published with an incorrect Web link. This document corrects that error.
FOR FURTHER INFORMATION CONTACT:
Astrid Lopez-Goldberg, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 5368, Silver Spring, MD 20993-0002, 301-796-3485, email@example.com.
In FR Doc. 2012-16475, appearing on page 40069 in the Federal Register of Friday, July 06, 2012, the following correction is made:
1. On page 40070, in the first column, in the last paragraph, the Web link “http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm238675.htm” is corrected to read “http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm238675.htm#narcotics”.
Dated: July 9, 2012.
Assistant Commissioner for Policy.
[FR Doc. 2012-17089 Filed 7-12-12; 8:45 am]
BILLING CODE 4160-01-P